6-(Tetrazol-5-yl)-7-aminoazolo[1,5-<i>a</i>]pyrimidines as Novel Potent CK2 Inhibitors
Grigoriy V. Urakov,
Konstantin V. Savateev,
Svetlana K. Kotovskaya,
Vladimir L. Rusinov,
Alexandr A. Spasov,
Denis A. Babkov,
Elena V. Sokolova
Affiliations
Grigoriy V. Urakov
Department of Organic and Biomolecular Chemistry, Ural Federal University Named after the First President of Russia B.N. Eltsin, Mira St. 19, 620002 Yekaterinburg, Russia
Konstantin V. Savateev
Department of Organic and Biomolecular Chemistry, Ural Federal University Named after the First President of Russia B.N. Eltsin, Mira St. 19, 620002 Yekaterinburg, Russia
Svetlana K. Kotovskaya
Department of Organic and Biomolecular Chemistry, Ural Federal University Named after the First President of Russia B.N. Eltsin, Mira St. 19, 620002 Yekaterinburg, Russia
Vladimir L. Rusinov
Department of Organic and Biomolecular Chemistry, Ural Federal University Named after the First President of Russia B.N. Eltsin, Mira St. 19, 620002 Yekaterinburg, Russia
Alexandr A. Spasov
Scientific Center for Innovative Drugs, Volgograd State Medical University, 400131 Volgograd, Russia
Denis A. Babkov
Scientific Center for Innovative Drugs, Volgograd State Medical University, 400131 Volgograd, Russia
Elena V. Sokolova
Scientific Center for Innovative Drugs, Volgograd State Medical University, 400131 Volgograd, Russia
In this work, we describe the design, synthesis, and structure-activity relationship of 6-(tetrazol-5-yl)-7-aminoazolo[1,5-a]pyrimidines as inhibitors of Casein kinase 2 (CK2). At first, we optimized the reaction conditions for the azide-nitrile cycloaddition in the series of 6-cyano-7-aminoazolopyridimines and sodium azide. The regioselectivity of this process has been shown, as the cyano group of the pyrimidine cycle was converted to tetrazole while the nitrile of the azole fragment did not react. The desired tetrazolyl-azolopyrimidines were obtained in a moderate to excellent yields (42–95%) and converted further to water soluble sodium salts by the action of sodium bicarbonate. The obtained 6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidines 2a–k and their sodium salts 3a–c, 3g–k showed nano to low micromolar range of CK2 inhibition while corresponding [1,2,4]triazolopyrimidines 10a–k were less active (IC50 > 10 µM). The leader compound 3-phenyl-6-(tetrazol-5-yl)-7-aminopyrazolo[1,5-a]pyrimidine 2i as CK2 inhibitor showed IC50 45 nM.